Bausch Health Canada has secured the listing of PrOKEDI dosages in the Régie de l'assurance maladie du Québec (RAMQ) public drug reimbursement formulary [1].
This listing ensures that patients in Québec have public financial access to an extended-release injectable suspension of risperidone. Because Québec is the first province to list the medication on its public formulary, the move establishes a potential precedent for other Canadian provinces to follow [3].
Bausch Health Companies Inc. (NYSE:BHC) announced the development on July 6, though the listing became effective on June 25 [2, 4]. The medication is used for the treatment of specific psychiatric conditions requiring long-acting injectable therapy [3].
The approved dosages included in the RAMQ formulary are the 75 mg and 100 mg strengths [3]. This inclusion allows the public healthcare system to cover the costs of these specific dosages for eligible patients.
Bausch Health operates as a global pharmaceutical company. Its Canadian subsidiary manages the distribution and regulatory approval process for these treatments within the region [1, 4].
Regarding the company's market position, Yahoo Finance Companies said, "Bausch Health Companies Inc. (NYSE:BHC) is one of the 15 best NYSE penny stocks to buy according to hedge funds" [1].
“Québec is the first province to list (Pr)OKEDI(MC) on the public drug reimbursement formulary”
The inclusion of PrOKEDI in the RAMQ formulary reduces the financial barrier for patients requiring long-term injectable risperidone. By becoming the first Canadian province to provide this public reimbursement, Québec may signal a shift in how other provincial health authorities evaluate the cost-benefit of extended-release psychiatric medications, potentially increasing the drug's overall market penetration in Canada.
